Objectives: To present preliminary results of minimally invasive endovascular embolization
as a treatment of symptomatic adenomyosis or adenomyosis with fibroids and to assess
the long-term clinical outcome. Material and methods: Between 2015 and 2020 twelve
patients with symptomatic adenomyosis or adenomyosis with fibroids underwent uterine
artery embolization (UAE). All patients were evaluated in terms of patient???s overall
satisfaction, relief of clinical symptoms, reintervention and hysterectomy as well
as menopause rates. Results: Mean age on admission was 48 years. Reported symptoms
included: dysmenorrhea with the mean VAS score of 7.8, menorrhagia and problems with
urination. Successful embolization was achieved in all patients (100%). A reduction
in pelvic pain intensity assessed using VAS was observed in 11/12 (92%) of the patients
??? pain decreased by 6.2 points on average (from 7.8 to 1.6 pts). In one patient
(8%) the recurrence of pain was observed. All patients reported decrease of menstrual
bleeding and consequently improvement of everyday life quality. Avoidance of hysterectomy
was achieved in 83% of the women. Five patients experience absence of menstrual periods
for at least 12 months after the embolization resulting in menopause rate of 42%.
Ten patients (83%) reported to be very or fairly satisfied with the results and would
recommend this treatment to a friend. Conclusions: Uterine artery embolization might
be safe and effective method of treatment for patients with symptomatic adenomyosis
with or without fibroids with very high rate of satisfied patients.
